Abstract
To the Editor.— In these days of increasing concerns about the steadily escalating costs of medical care in the United States, the publication of the article by Edelson et al 1 showing a sevenfold difference between the cost-effectiveness of different antihypertensive drugs in the treatment of mild to moderate hypertension is sure to receive considerable notice, if not by clinicians certainly by those people who are exerting more and more influence over the way clinicians practice medicine— third-party payers, health maintenance organizations' formulary committees, and health policy planners in Washington. Therefore, all who are interested in providing the best possible care for hypertensive patients ought to be aware that the data used to reach the conclusions of this analysis are seriously flawed. For example, the authors use as little as a single study involving 12 patients for one drug and compare it with another drug for which data are used
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
